Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Operating Leases (2018 - 2025)

Cytokinetics (CYTK) has disclosed Operating Leases for 8 consecutive years, with $108.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases changed N/A to $108.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $108.0 million, a N/A change, with the full-year FY2025 number at $108.0 million, changed N/A from a year prior.
  • Operating Leases was $108.0 million for Q4 2025 at Cytokinetics, down from $110.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $126.9 million in Q4 2022 to a low of $85.3 million in Q1 2021.
  • A 5-year average of $114.6 million and a median of $114.4 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: skyrocketed 25406.59% in 2021, then fell 6.11% in 2024.
  • Cytokinetics' Operating Leases stood at $112.2 million in 2021, then grew by 13.07% to $126.9 million in 2022, then decreased by 5.1% to $120.4 million in 2023, then dropped by 4.71% to $114.8 million in 2024, then fell by 5.91% to $108.0 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Operating Leases are $108.0 million (Q4 2025), $110.7 million (Q3 2025), and $111.0 million (Q2 2025).